Agenus Inc
AGEN2.940USD
+0.170+6.14%
Handelsschluss 02/06, 16:00（ET）Kurse um 15 Minuten verzögert
96.47MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Agenus Inc Unternehmen
Agenus Inc. is a clinical-stage biotechnology company specializing in discovering and developing therapies to activate the body's immune system against cancer and infections. The Company’s pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.), and vaccine adjuvants (via SaponiQx, Inc.). Its primary focus is immuno-oncology (I-O), and its diverse pipeline is supported by its in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. Its most advanced antibody candidates are botensilimab (a multifunctional immune cell activator and human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody) and balstilimab (a novel, fully human monoclonal immunoglobulin G4 (IgG4) PD-1 inhibitor). Its pipeline includes several classes of immunotherapies: checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents.
Agenus Inc Informationen
BörsenkürzelAGEN
Name des UnternehmensAgenus Inc
IPO-datumFeb 04, 2000
CEOArmen (Garo H)
Anzahl der mitarbeiter316
WertpapierartOrdinary Share
GeschäftsjahresendeFeb 04
Addresse3 Forbes Rd
StadtLEXINGTON
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl02421-7305
Telefon17816744400
Websitehttps://agenusbio.com/
BörsenkürzelAGEN
IPO-datumFeb 04, 2000
CEOArmen (Garo H)
Führungskräfte von Agenus Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Thomas L. (Tom) Harrison, Ph.D.
Mr. Thomas L. (Tom) Harrison, Ph.D.
Independent Director
Independent Director
29.77K
+7691.00%
Ms. Christine M. Klaskin
Ms. Christine M. Klaskin
Vice President - Finance
Vice President - Finance
23.48K
+15782.00%
Mr. Brian J. Corvese
Mr. Brian J. Corvese
Independent Director
Independent Director
4.60K
--
Wright (Timothy R)
Wright (Timothy R)
Lead Independent Director
Lead Independent Director
2.77K
--
Dr. Garo H. Armen, Ph.D.
Dr. Garo H. Armen, Ph.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Dr. Jennifer S. Buell, Ph.D.
Dr. Jennifer S. Buell, Ph.D.
Director
Director
--
--
Ms. Susan F. Hirsch
Ms. Susan F. Hirsch
Independent Director
Independent Director
--
--
Dr. Steven O'Day, M.D.
Dr. Steven O'Day, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Richard Goldberg
Mr. Richard Goldberg
Chief Development Officer
Chief Development Officer
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Thomas L. (Tom) Harrison, Ph.D.
Mr. Thomas L. (Tom) Harrison, Ph.D.
Independent Director
Independent Director
29.77K
+7691.00%
Ms. Christine M. Klaskin
Ms. Christine M. Klaskin
Vice President - Finance
Vice President - Finance
23.48K
+15782.00%
Mr. Brian J. Corvese
Mr. Brian J. Corvese
Independent Director
Independent Director
4.60K
--
Wright (Timothy R)
Wright (Timothy R)
Lead Independent Director
Lead Independent Director
2.77K
--
Dr. Garo H. Armen, Ph.D.
Dr. Garo H. Armen, Ph.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Dr. Jennifer S. Buell, Ph.D.
Dr. Jennifer S. Buell, Ph.D.
Director
Director
--
--
Umsatzaufteilung
Währung: USDAktualisiert: Tue, Jan 6
Währung: USDAktualisiert: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Non-cash royalty revenue
29.15M
96.40%
Clinical product revenue
1.09M
3.60%
Other services
0.00
0.00%
Nach RegionUSD
Name
Umsatz
Anteil
United States
30.23M
100.00%
Rest of World
0.00
0.00%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Non-cash royalty revenue
29.15M
96.40%
Clinical product revenue
1.09M
3.60%
Other services
0.00
0.00%
Aktionärsstatistik
Aktualisiert: Sat, Feb 7
Aktualisiert: Sat, Feb 7
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
7.83%
Zydus Lifesciences Ltd
5.90%
Invus Public Equities Advisors, LLC
2.94%
Morgan Stanley & Co. LLC
1.37%
BlackRock Institutional Trust Company, N.A.
1.30%
Andere
80.66%
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
7.83%
Zydus Lifesciences Ltd
5.90%
Invus Public Equities Advisors, LLC
2.94%
Morgan Stanley & Co. LLC
1.37%
BlackRock Institutional Trust Company, N.A.
1.30%
Andere
80.66%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
16.06%
Corporation
5.90%
Investment Advisor/Hedge Fund
4.37%
Hedge Fund
3.03%
Research Firm
2.80%
Individual Investor
1.68%
Pension Fund
0.34%
Andere
65.82%
Institutionelle Beteiligung
Aktualisiert: Mon, Dec 8
Aktualisiert: Mon, Dec 8
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
304
9.95M
37.38%
--
2025Q3
332
9.95M
41.39%
+217.92K
2025Q2
334
9.73M
47.54%
+407.61K
2025Q1
334
9.33M
45.75%
-2.82M
2024Q4
341
8.45M
52.98%
-249.79K
2024Q3
351
8.70M
54.68%
-447.45K
2024Q2
347
9.21M
64.12%
-1.91M
2024Q1
356
10.69M
65.28%
-2.98M
2023Q4
374
11.90M
61.88%
+645.94K
2023Q3
382
11.27M
62.51%
+267.62K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
The Vanguard Group, Inc.
2.57M
7.56%
+36.98K
+1.46%
Sep 30, 2025
Invus Public Equities Advisors, LLC
1.06M
3.13%
--
--
Sep 30, 2025
Morgan Stanley & Co. LLC
493.52K
1.45%
-226.23K
-31.43%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
468.79K
1.38%
-20.89K
-4.27%
Sep 30, 2025
Armen (Garo H.)
367.59K
1.08%
+9.26K
+2.58%
Dec 26, 2025
BofA Global Research (US)
369.31K
1.09%
-51.36K
-12.21%
Sep 30, 2025
Millennium Management LLC
348.75K
1.03%
-155.75K
-30.87%
Sep 30, 2025
Geode Capital Management, L.L.C.
346.99K
1.02%
+29.58K
+9.32%
Sep 30, 2025
Walleye Capital LLC
310.79K
0.91%
+112.50K
+56.74%
Sep 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
iShares Micro-Cap ETF
0.02%
iShares Russell 2000 Growth ETF
0%
iShares Russell 3000 ETF
0%
Invesco NASDAQ Future Gen 200 ETF
0%
Fidelity Enhanced Small Cap ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
Schwab U.S. Small-Cap ETF
0%
SPDR Portfolio MSCI Global Stock Market ETF
0%
Global X Russell 2000 ETF
0%
Virtus LifeSci Biotech Clinical Trials ETF
0%
Mehr Anzeigen
iShares Micro-Cap ETF
Anteil0.02%
iShares Russell 2000 Growth ETF
Anteil0%
iShares Russell 3000 ETF
Anteil0%
Invesco NASDAQ Future Gen 200 ETF
Anteil0%
Fidelity Enhanced Small Cap ETF
Anteil0%
iShares Core S&P Total U.S. Stock Market ETF
Anteil0%
Schwab U.S. Small-Cap ETF
Anteil0%
SPDR Portfolio MSCI Global Stock Market ETF
Anteil0%
Global X Russell 2000 ETF
Anteil0%
Virtus LifeSci Biotech Clinical Trials ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Feb 15, 2024
Merger
20→1
Feb 15, 2024
Merger
20→1
Feb 15, 2024
Merger
20→1
Feb 15, 2024
Merger
20→1
Datum
Ex-Dividendentag
Art
Verhältnis
Feb 15, 2024
Merger
20→1
Feb 15, 2024
Merger
20→1
Feb 15, 2024
Merger
20→1
Feb 15, 2024
Merger
20→1
